88 results about "Cellular proteins" patented technology

A device, method and process for three-dimensional spatial localization and functional interconnection of the same or different types of cells. The two or three-dimensional device comprising multiple layers containing wells for cell deposition where both the wells and layers are interconnected through microfluidic channels. A process for fabricating the three-dimensional device and a method for depositing different types of cells within the device in a functional interdependent spatial orientation thereby mimicking physiological functions. The device is useful for diagnostic assays, determination of dysfunction of certain cells in the system, quantification of production of cellular proteins, metabolites, hormones or other cellular products, for organ or tissue replacement, for co-culturing different cells, for testing pharmaceutical agents and as a bioreactor for production of biologicals.

An apparatus and method for preparing and culturing cells includes a chamber having an inlet and an outlet for introducing culture medium and air. A cell growth substrate placed in the chamber for cells anchored or embedded. The preferred embodiment of invention claims a novel process for controlling the platform form to tilt at one end, to maintain the seesaw and rocking movement for cultured process. The seesaw movement or rocking movement efficiently the nutrition, carbon dioxide and oxygen transfer during cultured process for production of cellular protein products or harvesting the cells.

Various nucleic acid-based matrixes are provided, comprising nucleic acid monomers as building blocks, as well as nucleic acids encoding proteins, so as to produce novel biomaterials. Methods of utilizing such biomaterials include delivery of biologically active agents, cell and tissue culture, and cell-free protein synthesis.

The present invention relates to a transplant rejection in an animal suppressed by administration of an antibody directed at a cell surface antigen selected from the group consisting of CD4, CD8, CD154, LFA-1, CD80, CD86 and ICAM-1, preferably an anti-CD4 antibody, together with a non-cellular protein antigen to generate in the animal a population of regulatory T-lymphocytes; reactivating said population of regulatory T-lymphocytes by further administration to the animal of the non-cellular protein antigen; and transplanting said organ or tissue whilst said population of regulatory T-lymphocytes is activated. Regulatory T cells can be generated ex vivo by culturing T cells with an antibody directed at a cell surface antigen selected from the group consisting of CD4, CD8, CD154, LFA-1, CD80, CD86 and ICAM-1, in the presence of cells that present either alloantigen or a non-cellular protein antigen. Ex vivo generated T-lymphocytes can be used as an alternative method of overcoming transplant rejection or in combination with the in vivo method. A similar approach can be adopted for the treatment of autoimmune conditions.

The present invention provides a method for inhibiting the proliferation of malignant and/or hyperplastic cells in a subject by administering to the subject a therapeutically effective amount of a guanosine rich oligonucleotide. The present invention also provides oligonucleotides which are capable of being specifically bound to a specific cellular protein which is nucleolin and/or nucleolin-like in nature, which is implicated in the proliferation of cells, specifically malignant and/or hyperplastic cells, and a method for their selection.

The present invention relates to multiphase protein separation methods capable of resolving large numbers of cellular proteins. The methods of the present invention provide protein profile maps for imaging and comparing protein expression patterns. The present invention provides alternatives to traditional 2-D gel separation methods for the screening of protein profiles.

A protein transduction method for efficiently delivery of exogenous proteins into mammalian cells is invented, which has the capability of targeting different cellular compartments and protection from degradation of the delivered proteins from cellular proteases. A composition for treat proteins has cation reagents, lipids and enhancers in a carrier. The method can be used in a number of ways including: production of large quantities of properly folded, post-translationally modified proteins using mammalian cell machinery, a in-cell fluorescence spectroscopy and imaging using small molecule fluorophores and a in-cell NMR spectroscopy using living mammalian cells. The method permits cell biology at atomic resolution that is physiologically and pathological relevant and permits protein therapy to treat human diseases. The method can also be used to deliver exogenous protein inside mammalian cells, wherein the exogenous proteins follow a similar secretion pathway as that of the endogenous protein.

The present invention relates to protein separation systems and methods capable of resolving and characterizing large numbers of cellular proteins. In particular, the present invention provides a novel mass mapping system and methods for the differential display of proteins. The present invention further provides novel methods for displaying differential protein expression between two samples. In particular, the present invention provides novel method of mapping differential expression of proteins in non-cancerous, pre-cancerous, and cancerous cells.

The invention relates to an anti-immunodeficiency virus antibody which binds to a cellular protein and diagnostic and therapuetic methods of using the same.

The present invention provides proteomic techniques that extend sensitive and quantitative analysis of proteins to post-translational modifications. Protein micro-arrays and/or multiplex coded-microbeads are used in combination with multilayered affinity interaction detection (MAID) methods that permit high throughput analysis of cellular protein modifications and functional protein interactions.

The invention discloses a sample pretreatment method based on flow combination ICP-MS (Inductively Coupled Plasma Mass Spectrometry) single cell protein detection, and belongs to the technical field of sample pretreatment of flow cytometry. The sample pretreatment method comprises the following steps: (1) collecting and transporting a whole blood sample; (2) performing PBMC (Peripheral Blood Mononuclear Cell) cell separation; (3) performing cell active dyeing; (4) performing cell stimulation; (5) performing cell immobilization; (6) performing surface antibody dyeing; (7) performing intracellular phosphorylated protein dyeing; (8) performing single cell labeling, and the like. With the combination of a metal element labeled antibody with cell surface antigen, labeled cells are mixed with beads as internal reference for standardization, dead cells and living cells are distinguished in the pretreatment process, then the situation that the testing result analysis and description are affected by too many dead cells is avoided, single cells are distinguished from cell dimmers, cell trimers or even cell multimers, and flow combination ICP-MS single cell protein detection requirements can be very well met.

A computing system automatically analyzes various drug or other compound targets using biologic activity data for cellular proteins, and develops a target/anti-target matrix identifying pharmacologically responsive targets intended for drug engagement, and pharmacologically responsive anti-targets intended for avoidance of drug engagement. The system separates compounds into subsets based on biological threshold data and groups proteins through pharmacological similarity. The system ranks protein groupings in generating the matrix and uses the rankings to recommend compounds and compound groupings for testing to treat a pathology. The system compares new compounds against the matrix to recommend new compounds for testing.

The present invention relates broadly to methods for stimulating neural progenitor cell migration to certain regions of the nervous system where the neural progenitor cell naturally would not migrate. These methods have wide interest in fields related to the development of therapeutic approaches for addressing a broad range of neurodegenerative and demyelinating pathologies of the central nervous system. In order to accomplish these various outcomes, the invention provides modalities for introducing into a cell of the CNS a substance that promotes polysialylation of a protein component of the cell. This process underlies various methods of the invention, such as a method of polysialylating a protein of the cell, a method of promoting migration of a neural progenitor cell from a first region of a brain to a second region of the brain, or a method of promoting a neural progenitor cell originating in a first region of a brain to differentiate in a second region of the brain. The methods described above provide the basis for various therapeutic methods disclosed in the invention. In one example a method is disclosed of inhibiting the development of, treating, or ameliorating a neurological pathology in a subject, wherein the method includes introducing into brain cells, located in a path starting in a location close to where neural progenitor cells are located and ending in an area of the CNS where it is desirable that the neural progenitor cells migrate to, of the subject a substance that promotes polysialyltransferase activity that polysialylates a protein of the cells. In a second example a method is disclosed of inhibiting the development of, treating, or ameliorating a neurological pathology in a subject, including administering to the subject a substance that promotes polysialyltransferase activity in an amount effective to treat the pathology.

This invention provides methods for inhibiting or treating infection by viruses, in particular pox viruses by modulating a kinase, in particular by inhibiting a host cell kinase, involved in mediating viral infection. Methods to identify, validate, and classify the cellular proteins required by viruses during infection of host cells in order to select agents which can inhibit viral infection are described herein. Using a systems biology approach the virus/host cell interaction is studied from initial attachment of the incoming virus to the cell surface, to entry, transcription, replication, biosynthesis, and assembly of progeny particles. The method employs a siRNA screening platform and uses gene silencing to map the ‘viral infectome’—a compilation of cellular proteins that the virus needs to establish infection and drive the infectious cycle. Charting the infectome provides information on the viral biology by the identification of host cell proteins involved in viral infection and allows the development of novel anti-viral drugs that prevent the viruses from establishing productive infection in cells.